



Xagenic Appoints Seasoned Industry Veteran Randall Wilhoite As Vice President of Operations

Wilhoite brings nearly three decades of healthcare operations experience to Company

Toronto, ON (August 25, 2015) – Xagenic, a molecular diagnostics company developing the Xagenic X1™ platform for use at the point of care, today announced that Randall Wilhoite has joined the Company as Vice President of Operations. Wilhoite will oversee manufacturing and operations to ensure the company's commercial objectives for the Xagenic X1 platform are met.

"We are aggressively pursuing the path to market for the Xagenic X1 platform, a system we believe to be a breakthrough in point of care diagnostics," commented Timothy I. Still, President and Chief Executive Officer of Xagenic. "In order to successfully ramp up production for clinical studies and commercialization, Xagenic has added a seasoned professional who will help our company transition from a pilot line to high volume manufacturing and distribution."

"Randy has the pedigree to help bring the X1 platform to market, as illustrated by successful tenures in the diagnostics divisions at Siemens and Abbott Laboratories, as well as by the work he has done bringing therapeutics from approval to market - all while achieving notable cost savings. We are delighted to have him join our team," Still added.

Wilhoite brings a wealth of operational experience in *in vitro* diagnostics to this newly-established role at Xagenic, most recently from Siemens Healthcare Diagnostics, where he directed point of care manufacturing. Prior to Siemens, Wilhoite held senior operations, logistics and supply chain roles at two Massachusetts-based companies – Oscient Pharmaceuticals Inc. and Anika Therapeutics Inc. He began his career in the diagnostics division of Abbott Laboratories Inc., where he spent 15 years in various roles within operations and received several awards for improved efficiency and cost reduction.

"The enzyme-free nature of the AuRA™ technology reduces product complexity, enables a low COGS and simplifies the logistics of producing, storing and shipping the Xagenic X1 cartridges on a commercial scale," Wilhoite said. "I look forward to leveraging my operational expertise in support of Xagenic's offering and believe that the attention and care that was dedicated to the design and development of the Xagenic platform has paved the way for optimized scale up to commercialization."

Wilhoite holds a bachelor's degree in chemistry from Indiana University in Bloomington, Indiana.

###

About Xagenic

Xagenic is a privately-held molecular diagnostics company developing the Xagenic X1™ platform, a revolutionary diagnostic system designed from its inception for use in a clinician's office. The Xagenic X1 platform will allow users to perform lab-quality molecular diagnostic tests in the physician office. With a time-to-result of 20 minutes, the system is poised to transform the way healthcare is delivered. The Company is backed by Domain Associates, CTI Life Sciences Fund, the Ontario Capital Growth Corporation, BDC Capital and Qiagen. Xagenic was the 2014 Frost & Sullivan Point-of-Care Diagnostics



New Product Innovation Leadership Award winner and the recipient of the 2015 Life Science Company of the Year award from Life Sciences Ontario. The Company is headquartered in Toronto with a San Francisco office. **For more information, please visit www.xagenic.com.**

For more information, contact:

Timothy I. Still
President & Chief Executive Officer
timothy.still@xagenic.com
1 (416) 363-1999 x1250

Media Contact:

Kirsten Thomas
The Ruth Group
kthomas@theruthgroup.com
1 (508) 280-6592